Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma

Michael R. Green, Andrew J. Gentles, Ramesh V. Nair, Jonathan M. Irish, Shingo Kihira, Chih Long Liu, Itai Kela, Erik S. Hopmans, June H. Myklebust, Hanlee Ji, Sylvia K. Plevritis, Ronald Levy, Ash A. Alizadeh

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Follicular lymphoma (FL) is currently incurable using conventional chemotherapy or immunotherapy regimes, compelling new strategies. Advances in high-throughput sequencing technologies that can reveal oncogenic pathways have stimulated interest in tailoring therapies toward actionable somatic mutations. However, for mutation-directed therapies to be most effective, the mutations must be uniformly present in evolved tumor cells as well as in the self-renewing tumor-cell precursors. Here, we show striking intratumoral clonal diversity within FL tumors in the representation of mutations in the majority of genes as revealed by whole exome sequencing of subpopulations. This diversity captures a clonal hierarchy, resolved using immunoglobulin somatic mutations and IGH-BCL2 translocations as a frame of reference and by comparing diagnosis and relapse tumor pairs, allowing us to distinguish early versus late genetic eventsduring lymphomagenesis. We provide evidence that IGHBCL2 translocations and CREBBP mutations are early events, whereas MLL2 and TNFRSF14 mutations probably represent late events during disease evolution. These observations provide insight into which of the genetic lesions represent suitable candidates for targeted therapies.

Original languageEnglish (US)
Pages (from-to)1604-1611
Number of pages8
JournalBlood
Volume121
Issue number9
DOIs
StatePublished - Feb 28 2013

Fingerprint

Follicular Lymphoma
Tumors
Mutation
Chemotherapy
Neoplasms
Immunoglobulins
Exome
Genes
Cells
Throughput
Immunotherapy
Therapeutics
Technology
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., ... Alizadeh, A. A. (2013). Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood, 121(9), 1604-1611. https://doi.org/10.1182/blood-2012-09-457283

Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. / Green, Michael R.; Gentles, Andrew J.; Nair, Ramesh V.; Irish, Jonathan M.; Kihira, Shingo; Liu, Chih Long; Kela, Itai; Hopmans, Erik S.; Myklebust, June H.; Ji, Hanlee; Plevritis, Sylvia K.; Levy, Ronald; Alizadeh, Ash A.

In: Blood, Vol. 121, No. 9, 28.02.2013, p. 1604-1611.

Research output: Contribution to journalArticle

Green, MR, Gentles, AJ, Nair, RV, Irish, JM, Kihira, S, Liu, CL, Kela, I, Hopmans, ES, Myklebust, JH, Ji, H, Plevritis, SK, Levy, R & Alizadeh, AA 2013, 'Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma', Blood, vol. 121, no. 9, pp. 1604-1611. https://doi.org/10.1182/blood-2012-09-457283
Green, Michael R. ; Gentles, Andrew J. ; Nair, Ramesh V. ; Irish, Jonathan M. ; Kihira, Shingo ; Liu, Chih Long ; Kela, Itai ; Hopmans, Erik S. ; Myklebust, June H. ; Ji, Hanlee ; Plevritis, Sylvia K. ; Levy, Ronald ; Alizadeh, Ash A. / Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. In: Blood. 2013 ; Vol. 121, No. 9. pp. 1604-1611.
@article{84f7c767b40c441887c1022e64ac8cb7,
title = "Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma",
abstract = "Follicular lymphoma (FL) is currently incurable using conventional chemotherapy or immunotherapy regimes, compelling new strategies. Advances in high-throughput sequencing technologies that can reveal oncogenic pathways have stimulated interest in tailoring therapies toward actionable somatic mutations. However, for mutation-directed therapies to be most effective, the mutations must be uniformly present in evolved tumor cells as well as in the self-renewing tumor-cell precursors. Here, we show striking intratumoral clonal diversity within FL tumors in the representation of mutations in the majority of genes as revealed by whole exome sequencing of subpopulations. This diversity captures a clonal hierarchy, resolved using immunoglobulin somatic mutations and IGH-BCL2 translocations as a frame of reference and by comparing diagnosis and relapse tumor pairs, allowing us to distinguish early versus late genetic eventsduring lymphomagenesis. We provide evidence that IGHBCL2 translocations and CREBBP mutations are early events, whereas MLL2 and TNFRSF14 mutations probably represent late events during disease evolution. These observations provide insight into which of the genetic lesions represent suitable candidates for targeted therapies.",
author = "Green, {Michael R.} and Gentles, {Andrew J.} and Nair, {Ramesh V.} and Irish, {Jonathan M.} and Shingo Kihira and Liu, {Chih Long} and Itai Kela and Hopmans, {Erik S.} and Myklebust, {June H.} and Hanlee Ji and Plevritis, {Sylvia K.} and Ronald Levy and Alizadeh, {Ash A.}",
year = "2013",
month = "2",
day = "28",
doi = "10.1182/blood-2012-09-457283",
language = "English (US)",
volume = "121",
pages = "1604--1611",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma

AU - Green, Michael R.

AU - Gentles, Andrew J.

AU - Nair, Ramesh V.

AU - Irish, Jonathan M.

AU - Kihira, Shingo

AU - Liu, Chih Long

AU - Kela, Itai

AU - Hopmans, Erik S.

AU - Myklebust, June H.

AU - Ji, Hanlee

AU - Plevritis, Sylvia K.

AU - Levy, Ronald

AU - Alizadeh, Ash A.

PY - 2013/2/28

Y1 - 2013/2/28

N2 - Follicular lymphoma (FL) is currently incurable using conventional chemotherapy or immunotherapy regimes, compelling new strategies. Advances in high-throughput sequencing technologies that can reveal oncogenic pathways have stimulated interest in tailoring therapies toward actionable somatic mutations. However, for mutation-directed therapies to be most effective, the mutations must be uniformly present in evolved tumor cells as well as in the self-renewing tumor-cell precursors. Here, we show striking intratumoral clonal diversity within FL tumors in the representation of mutations in the majority of genes as revealed by whole exome sequencing of subpopulations. This diversity captures a clonal hierarchy, resolved using immunoglobulin somatic mutations and IGH-BCL2 translocations as a frame of reference and by comparing diagnosis and relapse tumor pairs, allowing us to distinguish early versus late genetic eventsduring lymphomagenesis. We provide evidence that IGHBCL2 translocations and CREBBP mutations are early events, whereas MLL2 and TNFRSF14 mutations probably represent late events during disease evolution. These observations provide insight into which of the genetic lesions represent suitable candidates for targeted therapies.

AB - Follicular lymphoma (FL) is currently incurable using conventional chemotherapy or immunotherapy regimes, compelling new strategies. Advances in high-throughput sequencing technologies that can reveal oncogenic pathways have stimulated interest in tailoring therapies toward actionable somatic mutations. However, for mutation-directed therapies to be most effective, the mutations must be uniformly present in evolved tumor cells as well as in the self-renewing tumor-cell precursors. Here, we show striking intratumoral clonal diversity within FL tumors in the representation of mutations in the majority of genes as revealed by whole exome sequencing of subpopulations. This diversity captures a clonal hierarchy, resolved using immunoglobulin somatic mutations and IGH-BCL2 translocations as a frame of reference and by comparing diagnosis and relapse tumor pairs, allowing us to distinguish early versus late genetic eventsduring lymphomagenesis. We provide evidence that IGHBCL2 translocations and CREBBP mutations are early events, whereas MLL2 and TNFRSF14 mutations probably represent late events during disease evolution. These observations provide insight into which of the genetic lesions represent suitable candidates for targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=84876460347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876460347&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-09-457283

DO - 10.1182/blood-2012-09-457283

M3 - Article

C2 - 23297126

AN - SCOPUS:84876460347

VL - 121

SP - 1604

EP - 1611

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -